Leveraging SARS-CoV-2 Main Protease (Mpro) for COVID-19 Mitigation with Selenium-Based Inhibitors

Viviana De Luca,Andrea Angeli,Alessio Nocentini,Paola Gratteri,Silvia Pratesi,Damiano Tanini,Vincenzo Carginale,Antonella Capperucci,Claudiu T. Supuran,Clemente Capasso

DOI: https://doi.org/10.3390/ijms25020971

IF: 5.6

2024-01-13

International Journal of Molecular Sciences

Abstract:The implementation of innovative approaches is crucial in an ongoing endeavor to mitigate the impact of COVID-19 pandemic. The present study examines the strategic application of the SARS-CoV-2 Main Protease (Mpro) as a prospective instrument in the repertoire to combat the virus. The cloning, expression, and purification of Mpro, which plays a critical role in the viral life cycle, through heterologous expression in Escherichia coli in a completely soluble form produced an active enzyme. The hydrolysis of a specific substrate peptide comprising a six-amino-acid sequence (TSAVLQ) linked to a p-nitroaniline (pNA) fragment together with the use of a fluorogenic substrate allowed us to determine effective inhibitors incorporating selenium moieties, such as benzoselenoates and carbamoselenoates. The new inhibitors revealed their potential to proficiently inhibit Mpro with IC50-s in the low micromolar range. Our study contributes to the development of a new class of protease inhibitors targeting Mpro, ultimately strengthening the antiviral arsenal against COVID-19 and possibly, related coronaviruses.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The problem this paper attempts to address is the development of new selenium-based inhibitors to combat the novel coronavirus (SARS-CoV-2). Specifically, the research team cloned, expressed, and purified the main protease (Mpro) of SARS-CoV-2, an enzyme that plays a critical role in the virus's lifecycle. By using Escherichia coli for heterologous expression, they successfully obtained a fully soluble form of the active enzyme. The study further utilized specific substrate peptides (containing the TSAVLQ sequence, linked to a p-nitroaniline fragment) and fluorescent substrates to identify several selenium-containing inhibitors, such as benzisoselenazolone and selenocarbamates. These new inhibitors demonstrated a high capacity to inhibit Mpro, with IC50 values in the low micromolar range. This research contributes to the development of a new class of protease inhibitors targeting Mpro, thereby enhancing the antiviral arsenal against the novel coronavirus and related coronaviruses.